October 11, 2017 6:13pm
We are b a c k … the oversold
As sentiment provokes momentum fleeing the overbought
Out and about: The rumor is that Pluristem (PSTI) is seeking to sell products to mundipharma (http://www.mundipharma.com) as PSTI jumps +$0.25
Pre-open indications: 3 hit and 1 miss
If you had been right as many times as I have been in these many months of 2017 as a SUBSCRIBER you would know when to get in or out and even get back in again!
In the grip of rotating cycles and disparaging trends, what is the price of sector equities - knowledge and a subscription!
Wednesday’s results have implications to Thursday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
The way forward cannot be found in the practices and spending of the past as the sector is operating and defined by its own contradictions.
Henry’omics:
From the pre-open’s newsletter, “the big squeeze as investors continue swinging from and to some newer highs, they also know that any dramatic upside can have a negative portfolio impact “
I am NOT crying a river over today’s oversold as they will resume the runway back to being overbought and another downside as Q results get closer.
What is getting to me … is the emphasis on … EXPOSURE to ETFs in the sector!
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The open was neutral with an A/DL of 20/20 and 3 flats;
· The mid-day was negative with an A/DL of 16/22 and 5 flats;
· The close was negative with an A/DL of 14/26 and 3 flat;
Pre-open indications: 3 hit and 1 miss
- Athersys (ATHX) closed up +$0.16 – hit;
- Biostage (BSTG) closed down -$0.01 – hit;
- MiMedx (MDXG) closed up +$0.03 – hit;
- Spark Therapeutics (ONCE) closed down -$0.54 – miss;
Some of MY working trend lines or indications:
… The greatest volume to the downside: IMUC, ONVO, BSTG, CYTX and XON
… Upside volume was weighted to: ATHX, PSTI, MDXG, CAPR and SGMO
… Biggest $ downside: BLUE (-$6.20), XON (-$0.83), ONCE (-$0.54), QURE (-$0.28) and BLCM (-$0.22)
… Largest $ upside: CLLS (+$0.70), RGNX (+$0.65), STML (+$0.35), VCEL (+$0.30) and VCEL (+$0.25)
… Flat: OSIR at $4.55, KITE at $179.79 and RENE.L at $1.75
Counting the week’s apples:
Biostage (BSTG) closed down -$0.01 (when isn’t it) – my question is … WHO and WHEN are they (shareholder lawsuits) going to DRAIN the SWAMP of this BOD and management team who have missed or ignored the signs or signals of demise …! Does ANYONE believe that the same team that drowned the company in the toilet can resuscitate the real victims - its shareholders? I say call the … SEC;
CAPR closed up +40.16 after being down -$0.21 after Monday’s -$0.19 - CAPR can’t keep fooling investors for long with their brand of hype …
VCEL was up +$0.30 after Tuesday’s +$0.05 after Monday’s -$0.40 – still believe an Icarus flight path and should have financed in an overnight … does every up have a big down, let’s see …
As HSGX closed up +$0.01 after being down -$0.02 after Monday’s -$0.07 after a week of ups (+$0.21) … traders are nervous … I like the company i.e. undervalued …
While AXGN was down -$0.20 after being up +$0.05 after being flat on Monday while MDXG was up +$0.03 post regaining momentum with a +$0.61 jump after being down -$0.41 … the merry-go-round turns – I’ll ride the moving horse;
AGTC was down again another -$0.15 after Monday’s +$0.05 and being flat at $4.00 on Friday … AGTC can’t escape the downside trap … while its management is deaf, dumb or blind?
AST was down again -$0.05 while mothership BTX was down -$0.03 post being up +$0.04 … they both NEED cash to prop their balance sheets
Cellectis S.A. (CLLS) jumped again +40.70 after Tuesday’s +$0.44 after being down -$0.19 after Friday’s -$0.28 as I had stated … if you stay on the merry-go-round, don’t wait for the music to stop;
Immuno-oncologists - JUNO was down again -$0.19 after being -$0.49 after Monday’s +$0.07 after Friday’s -$1.11; as VSTM dumped -$0.07 after having jumped +$0.06 after slipping -$0.01 on Monday post last Friday’s -$0.14;
ATHX was up +$0.16 after declining -$0.19 after being flat after Friday’s -$0.03 as many STILL question their cash position going forward as their clinical “manufacturing” batch issues might be solved but, how are they going to pay for the future …
RGNX was up +$0.65 after being up +$0.75 after being down -$1.35 after Friday’s +$0.50, as I have stated RGNX bounds … I keep telling you to stay!
SGMO was up again +$0.25 after Tuesday’s +$0.05 after getting slashed -$0.10 after Friday’s -$0.70 while ONCE was down -$0.54 after being up +$1.07 after Monday’s -$1.77
As BLUE feels the pain of being overbought having jumped again +$0.15 post being +$3.75 after last Friday’s +$1.75 … a soccer ball;
FATE was down again -$0.05 after Tuesday’s -$0.02 following Monday’s +$0.06– hang in;
MESO regained some more altitude +$0.06 after Tuesday’s +$0.61 after Monday’s -$0.06 post last Friday’s -$0.30 – as I had stated time to be accumulating …
PSTI was up +$0.25 after Tuesday’s +$0.08 after Monday’s +$0.07 following rumor of selling some product assets…
Daily analytics:
U.S. stock benchmarks closed at records on Wednesday after minutes from the Fed's policy-setting gathering in September indicated a desire to increase rates one additional time despite stubbornly low inflation.
· The Dow rose about 42.21 points, or 0.2%, at 22,872.89
· The S&P 500 index ended about 4.6 points, or 0.2%, at 2,555.24
· While the NASDAQ climbed 16.30 points, or 0.3%, to 6,603.55
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Wednesday traded at 9.83, down -2.48% …
- Tuesday traded at 10.08, down -2.42% after Monday traded at 10.33, up +7.05% after Friday traded 9.65, up +5.01% after Thursday traded at 9.19, down -4.57% after last Wednesday traded at 9.63, up +1.26% …
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Wednesday was down -0.09%
· Tuesday+0.27%
· Monday -0.41%
· Friday -0.11%
· Thursday +0.27%
· Last Wednesday -0.30%
… The Russell 2000 (RUT)
· Wednesday lost -1.08 or -0.07%
· Tuesday was gained +4.44 or +0.30%
· Monday lost -6.66 or -0.44%
· Friday lost -1.87 points or -0.12%
· Thursday gained 4.32 points, or 0.3%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Wednesday was down -0.21%
· Tuesday +0.03%
· Monday -0.29%
· Friday -0.11%
· Thursday +0.11%
· Last Wednesday +0.78%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %
· Wednesday’s decliners ranged from -0.44% <JUNO -$0.19> to -9.84% <BSTG -$0.01> in 26 equities;
· Tuesday’s decliners ranged from -0.42% <XON -$0.08> to -12.82% <ONVO -$0.25)> in 19 equities;
· Monday’s decliners ranged from -0.22% <VSTM -$0.01> to -14.95% <CYTX -$0.0949> in 26 equities;
· Friday’s decliners ranged from -0.05% <ONCE -$0.04> to -52.40% <BSTG -$0.119> in 28 equities;
· Thursday’s decliners ranged from -0.05% <ONCE -$0.04> to -24.99% <BSTG -$0.08> in 21 equities;
· Last Wednesday’s decliners ranged from -0.42% <JUNO -$0.19> to -8.32% <KOOL -$0.40> in 16 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Wednesday’s gainers ranged from +0.24% <MDXG +$0.03> to +15.24% <PSTI +$0.25> in 14 equities;
· Tuesday’s gainers ranged from +0.11% <BLUE +$0.15> to +10.02% <MESO +$0.61> in 23 equities;
· Monday’s gainers ranged from +0.16% <JUNO +$0.07> to +12.12% <RENE.L +$0.20> in 13 equities;
· Friday’s gainers ranged from +0.36% <BTX +$0.01> to +29.55% <CYTX +$0.14> in 12 equities;
· Thursday’s gainers ranged from +0.22% <OSIR -$0.01> to +24.49% <CYTX +$0.10> in 20 equities;
· Last Wednesday’s gainers ranged from +0.42% <VCEL +$0.025> to +6.38% <CYTX +$0.023> in 22 equities;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
